Protocol Ledger

NCT04690556 · Phase III · COMPLETED

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Interventional Phase III clinical trial protocol NCT04690556 sponsored by Lupin in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-14 Enrollment: 600 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04690556
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04690556
Protocol FieldVerified Registry Value
NCT IdentifierNCT04690556
Consolidated Lead SponsorLupin
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment600 participants (ACTUAL)
Registered Start Date2020-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04690556
Hospital Research SiteLocationSite Profile
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI